Anti-Infective Drugs Market, By Drug Class, By Indication, By Route of Administration, By End-User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

Description

The Anti-Infective Drugs Market size was valued at US$ 134,267.21 Million in 2024, expanding at a CAGR of 3.1% from 2025 to 2032.

The anti-infective drugs market focuses on the development and distribution of medications used to prevent and treat infections caused by bacteria, viruses, fungi, and parasites. The rising incidence of hospital-acquired infections and increasing antibiotic resistance have pushed pharmaceutical companies like Pfizer and GlaxoSmithKline to expand their R&D pipelines for novel antimicrobials. For example, the WHO reported that over 4.95 million deaths in 2023 were linked to drug-resistant bacterial infections, creating urgent demand for advanced therapies. Partnerships between biotech firms and academia are supporting the development of next-generation antibiotics and antivirals. However, high development costs and declining profitability of antibiotics discourage smaller players from entering the market. Expanding access to treatments in emerging economies and the rising focus on combination therapies present opportunities for companies to diversify product portfolios and improve patient outcomes.

Anti-Infective Drugs Market- Market Dynamics

Rising Infection Burden and Antimicrobial Resistance Fuel Innovation in Anti-Infective Drugs

Rising infection rates and growing antimicrobial resistance are pushing global health agencies and pharmaceutical companies to accelerate innovation in anti-infective drugs. According to the WHO, antimicrobial resistance was responsible for 1.27 million direct deaths a year, with an additional 3.68 million deaths associated with drug-resistant infections. This has led organizations like the U.S. Centers for Disease Control and Prevention (CDC) to fund initiatives for rapid diagnostic tools and novel antibiotics. Governments are also supporting public-private partnerships, such as the AMR Action Fund, to address the dwindling antibiotic pipeline. These efforts are encouraging the development of new classes of antimicrobials, targeted antivirals, and combination therapies to combat resistant pathogens more effectively.

Anti-Infective Drugs Market- Segmentation Analysis:

The Global Anti-Infective Drugs Market is segmented on the basis of Drug Class, Indication, Route of Administration, End-User, and Region.

The market is divided into four categories based on Drug Class: Antibacterial, Antifungals, Antiparasitic, and Antivirals. Antibacterials hold the highest share due to widespread bacterial infection treatments, followed by antivirals driven by rising viral outbreaks. Antifungals rank next with the growing incidence of invasive fungal infections, while antiparasitics represent a smaller but crucial niche segment globally.

The market is divided into nine categories based on Indication: Pneumonia, Sepsis, Tuberculosis, Dermatophytosis, Candidiasis, Hepatitis virus infection, HIV infection, Covid-19 Virus, and Methicillin-resistant Staphylococcus Aureus. Pneumonia leads due to its high global burden, followed by sepsis, as critical care demand rises. HIV and hepatitis infections hold strong shares with ongoing treatment programs, while tuberculosis and MRSA drive antibiotic development. Candidiasis, dermatophytosis, and COVID-19 represent targeted therapeutic segments.

Anti-Infective Drugs Market- Geographical Insights

North America leads the anti-infective drugs market due to strong healthcare infrastructure and continuous R&D investments by players like Pfizer and Merck. In 2018, Pfizer collaborated with BioNTech to expand mRNA-based anti-infective applications beyond COVID-19, strengthening its regional presence. Europe follows closely, supported by EU-funded antimicrobial resistance (AMR) programs and partnerships like GSK's collaboration with BARDA to develop new antibiotics. Asia-Pacific is emerging as a key growth hub, driven by rising infection rates and government efforts to improve access to treatments; for instance, India's National Action Plan on AMR promotes antibiotic stewardship and local production. Latin America and MEA witness growing vaccine adoption and public health campaigns.

Anti-Infective Drugs Market- Country Insights

The United States dominates the North American anti-infective drugs market, supported by advanced healthcare systems and a robust pipeline of clinical trials. In 2024, Merck acquired Prometheus Biosciences to strengthen its immunology and infectious disease portfolio, enhancing its research capabilities. The U.S. government's Biomedical Advanced Research and Development Authority (BARDA) continues funding collaborations with companies like GSK and Venatorx Pharmaceuticals to accelerate antibiotic development. Rising cases of multidrug-resistant infections reported by the CDC are prompting hospitals to adopt newer therapies and diagnostic tools. Strong regulatory frameworks from the FDA and incentives like the GAIN Act further encourage innovation and commercialization of novel anti-infectives.

Anti-Infective Drugs Market- Competitive Landscape:

The competitive landscape of the anti-infective drugs market is shaped by leading players such as Pfizer, Merck, GSK, Johnson & Johnson, and Roche, who are expanding portfolios through R&D and strategic deals. In 2020, Pfizer partnered with Gilead Sciences to co-develop new antiviral combinations targeting resistant infections. GSK's collaboration with BARDA supports the development of next-generation antibiotics, while Johnson & Johnson invests in bacteriophage research to combat superbugs. Smaller biotech firms like Venatorx Pharmaceuticals and Iterum Therapeutics are entering collaborations with big pharma to scale manufacturing and distribution. This mix of partnerships, acquisitions, and government-backed programs is intensifying competition and accelerating drug innovation.

Recent Developments:

In February 2025, the Merieux Foundation, SPIM, and WHO launched a new Guide to Prescribing Anti-infective Drugs in Madagascar, updating antibiotic chapters, diagnostics, and integrating WHO's 2023 AWaRe classification to support standardized prescribing and strengthen national AMR action plans.

In February 2025, the U.S. FDA approved EMBLAVEO(TM) (aztreonam + avibactam) for adult patients with complicated intra-abdominal infections when few or no treatment options exist, including infections by E. coli and Klebsiella.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ANTI-INFECTIVE DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

AbbVie
AstraZeneca
Bayer
Cipla
Dr. Reddy's Laboratories
Gilead Sciences
GlaxoSmithKline (GSK)
Glenmark Pharmaceuticals
Johnson & Johnson
Lupin
Merck & Co.
Novartis
Pfizer
Roche
Sandoz (Novartis)
Sanofi
Sun Pharmaceutical Industries
Teva Pharmaceutical Industries
Viatris
ViiV Healthcare
Others

GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

Antibacterial
B-Lactams
Quinolones
Macrolides
Tetracycline
Aminoglycoside
Others
Antifungals
Azoles
Echinocandins
Polyenes
Antiparasitics
Antivirals

GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

Pneumonia
Sepsis
Tuberculosis
Dermatophytosis
Candidiasis
Hepatitis virus infection
HIV infection
Covid-19 Virus
Methicillin-resistant Staphylococcus Aureus
Others

GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Oral
Injectable
Topical
Inhalation

GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

Hospitals
Clinics
Retail Pharmacies
Institutional Buyers

GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

Product Code: ANV5742

1. Anti-Infective Drugs Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Anti-Infective Drugs Market Snippet by Drug Class
- 2.1.2. Anti-Infective Drugs Market Snippet by Indication
- 2.1.3. Anti-Infective Drugs Market Snippet by Route of Administration
- 2.1.4. Anti-Infective Drugs Market Snippet by End-User
- 2.1.5. Anti-Infective Drugs Market Snippet by Country
- 2.1.6. Anti-Infective Drugs Market Snippet by Region
2.2. Competitive Insights

3. Anti-Infective Drugs Key Market Trends

3.1. Anti-Infective Drugs Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Anti-Infective Drugs Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Anti-Infective Drugs Market Opportunities
3.4. Anti-Infective Drugs Market Future Trends

4. Anti-Infective Drugs Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Anti-Infective Drugs Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Anti-Infective Drugs Market Landscape

6.1. Anti-Infective Drugs Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Anti-Infective Drugs Market - By Drug Class

7.1. Overview
- 7.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
- 7.1.2. Antibacterial
  - 7.1.2.1. B-Lactams
  - 7.1.2.2. Quinolones
  - 7.1.2.3. Macrolides
  - 7.1.2.4. Tetracycline
  - 7.1.2.5. Aminoglycoside
  - 7.1.2.6. Others
- 7.1.3. Antifungals
  - 7.1.3.1. Azoles
  - 7.1.3.2. Echinocandins
  - 7.1.3.3. Polyenes
- 7.1.4. Antiparasitics
- 7.1.5. Antivirals

8. Anti-Infective Drugs Market - By Indication

8.1. Overview
- 8.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
- 8.1.2. Pneumonia
- 8.1.3. Sepsis
- 8.1.4. Tuberculosis
- 8.1.5. Dermatophytosis
- 8.1.6. Candidiasis
- 8.1.7. Hepatitis virus infection
- 8.1.8. HIV infection
- 8.1.9. Covid-19 Virus
- 8.1.10. Methicilin-resistant Staphylococcus Aureus
- 8.1.11. Others

9. Anti-Infective Drugs Market - By Route of Administration

9.1. Overview
- 9.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
- 9.1.2. Oral
- 9.1.3. Injectable
- 9.1.4. Topical
- 9.1.5. Inhalation

10. Anti-Infective Drugs Market - By End-User

10.1. Overview
- 10.1.1. Segment Share Analysis, By End-User, 2024 & 2032 (%)
- 10.1.2. Hospitals
- 10.1.3. Clinics
- 10.1.4. Retail Pharmacies
- 10.1.5. Institutional Buyers

11. Anti-Infective Drugs Market- By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. Anti-Infective Drugs Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.2.8. U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. Anti-Infective Drugs Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.9. UK
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.9.3. UK Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.9.4. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.9.5. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.9.6. UK Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.10. France
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.10.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.10.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.10.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.10.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.11. Italy
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.11.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.11.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.11.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.11.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.12. Spain
  - 11.3.12.1. Overview
  - 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.12.3. Spain Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.12.4. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.12.5. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.12.6. Spain Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.13. The Netherlands
  - 11.3.13.1. Overview
  - 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.13.3. The Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.13.4. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.13.5. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.13.6. The Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Overview
  - 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.14.6. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.15. Russia
  - 11.3.15.1. Overview
  - 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.15.3. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.15.4. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.15.5. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.15.6. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.16. Poland
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.16.3. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.16.4. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.16.5. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.16.6. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.17. Rest of Europe
  - 11.3.17.1. Overview
  - 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.17.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.17.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.3.17.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.17.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Anti-Infective Drugs Key Manufacturers in Asia Pacific
- 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.4.4. APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.4.5. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.4.6. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.4.7. APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.8. China
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.8.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.8.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.8.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.8.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.9. India
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.9.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.9.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.9.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.9.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.13. Indonesia
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.13.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.13.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.13.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.14. Thailand
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.14.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.14.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.14.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.14.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.16. Rest of APAC
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.16.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5. Latin America (LATAM)
- 11.5.1. Overview
- 11.5.2. Anti-Infective Drugs Key Manufacturers in Latin America
- 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.5.4. LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.5.5. LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.5.6. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.5.7. LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa (MEA)
- 11.6.1. Overview
- 11.6.2. Anti-Infective Drugs Key Manufacturers in Middle East and Africa
- 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.6.4. MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.6.5. MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.6.6. MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.6.7. MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.14. Rest of MEA
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.14.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Anti-Infective Drugs Industry

12.1. Competitive Dashboard
- 12.1.1. Competitive Benchmarking
- 12.1.2. Competitive Positioning
12.2. Company Profiles
- 12.2.1. AbbVie
- 12.2.2. AstraZeneca
- 12.2.3. Bayer
- 12.2.4. Cipla
- 12.2.5. Dr. Reddy's Laboratories
- 12.2.6. Gilead Sciences
- 12.2.7. GlaxoSmithKline (GSK)
- 12.2.8. Glenmark Pharmaceuticals
- 12.2.9. Johnson & Johnson
- 12.2.10. Lupin
- 12.2.11. Merck & Co.
- 12.2.12. Novartis
- 12.2.13. Pfizer
- 12.2.14. Roche
- 12.2.15. Sandoz (Novartis)
- 12.2.16. Sanofi
- 12.2.17. Sun Pharmaceutical Industries
- 12.2.18. Teva Pharmaceutical Industries
- 12.2.19. Viatris
- 12.2.20. ViiV Healthcare
- 12.2.21. Others

13. 360 Degree AnalystView

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us